Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
12 hedge funds and large institutions have $5.25M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 529 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
98% less funds holding
Funds holding: 546 → 12 (-534)
98% less capital invested
Capital invested by funds: $338M → $5.25M (-$333M)
100% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 529
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$2.15M |
| 2 |
TNB
Thomasville National Bank
Thomasville,
Georgia
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$47.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$20.6M |
| 3 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$17.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.8M |
| 5 |
BFS
Bard Financial Services
Branford,
Connecticut
|
-$13.7M |
BMY.RT Hedge Fund Activity: Q1 2021 in Review
12 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q1 2021, worth a combined $5.25M — down 98% from $338M a quarter earlier.
Sellers outnumbered buyers: 529 funds closed out of BMY.RT and 2 opened new positions — a net loss of 527 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Jet Capital Investors, adding an estimated $2.15M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $47.7M sold.
- 12 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q1 2021, down from 546 in Q4 2020.
- Funds reported $5.25M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q1 2021, down 98% quarter-over-quarter.
- 2 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q1 2021 and 529 closed out, a net change of -527 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q1 2021 was Jet Capital Investors, an estimated $2.15M added.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q1 2021 was Pentwater Capital Management, an estimated $47.7M sold.
Based on aggregated 13F filings for Q1 2021.